Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

Published:2008-10-27 Issue:1 Volume:8 Page:
ISSN:1472-6823
Container-title:BMC Endocrine Disorders
language:en
Short-container-title:BMC Endocr Disord

Author:

Williams-Herman Debora,Round Elizabeth,Swern Arlene S,Musser Bret,Davies Michael J,Stein Peter P,Kaufman Keith D,Amatruda John M

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/article/10.1186/1472-6823-8-14/fulltext.html

Reference40 articles.

1. Herman GA, Stein PP, Thornberry NA, Wagner JA: Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther. 2007, 81: 761-767. 10.1038/sj.clpt.6100167.

2. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M: Pharmacokinetics and pharmacodynamics of single doses of sitagliptin, an inhibitor of dipeptidyl peptidase-IV, in healthy subjects. Clin Pharm Therap. 2005, 78: 675-688. 10.1016/j.clpt.2005.09.002.

3. Drucker DJ, Nauck MA: GLP-1R agonists (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) for the treatment of type 2 diabetes. Lancet. 2006, 368: 1696-1705. 10.1016/S0140-6736(06)69705-5.

4. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE: Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006, 29: 2632-2637. 10.2337/dc06-0703.

5. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006, 49: 2564-2571. 10.1007/s00125-006-0416-z.

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors contributing to the adverse drug reactions associated with the dipeptidyl peptidase-4 (DPP-4) inhibitors: A scoping review;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2023-07

2. Evolving New Chemistry: Biocatalysis for the Synthesis of Amine-Containing Pharmaceuticals;Catalysts;2022-05-30

3. Angioedema associated with dipeptidyl peptidase-IV inhibitors;Clinical and Molecular Allergy;2021-12

4. Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity?;Biochemical Pharmacology;2021-06

5. Dipeptidyl peptidase‐4 inhibitor treatment and the risk of bullous pemphigoid and skin‐related adverse events: A systematic review and meta‐analysis of randomized controlled trials;Diabetes/Metabolism Research and Reviews;2020-08-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3